FX.co ★ Neurocrine's Ingrezza Shows Positive Data For Reduction Of Huntington's Disease Chorea

Neurocrine Biosciences, Inc. (NBIX) disclosed promising results from its KINECT-HD study, highlighting the beneficial effects of Ingrezza capsules on the emotional well-being and psychiatric stability of individuals experiencing chorea due to Huntington's disease. Chorea, characterized by involuntary and irregular movements, is a common symptom of Huntington's disease, a genetic and progressively worsening neurodegenerative condition. In this phase 3 clinical trial, the effectiveness of Ingrezza was measured against a placebo using the Unified Huntington's Disease Rating Scale - Total Maximal Chorea score. The study demonstrated consistent efficacy of Ingrezza in alleviating chorea symptoms across various patient subgroups, alongside potential improvements in emotional health. As of now, Neurocrine's shares are trading at $126.32 on the Nasdaq, reflecting an increase of 0.82 percent.